Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study
Our results confirm tildrakizumab as an effective treatment option for improving the HRQoL of patients with psoriasis.
Authors
- Teresa Battista (ORCID: https://orcid.org/0000-0002-1136-637X)
- Matteo Megna (ORCID: https://orcid.org/0000-0003-1803-2046)
- Angelo Ruggiero (ORCID: https://orcid.org/0000-0002-4658-7391)
- Luca Potestio (ORCID: https://orcid.org/0000-0001-5940-0592)
- Massimiliano Scalvenzi (ORCID: https://orcid.org/0000-0002-9912-3611)
- Sara Cacciapuoti (ORCID: https://orcid.org/0000-0002-3864-216X)
Institutions
- University of Naples Federico II (IT)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1093/ced/llae433
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.48